Skip to main content

Advertisement

SpringerLink
Log in

Clinical Applications of Melatonin in Radiotherapy: a Review

  • Medicine
  • Published:
SN Comprehensive Clinical Medicine Aims and scope Submit manuscript

Abstract

Radiotherapy is a treatment method for cancers using ionizing radiation (IR). Radiotherapy-induced complications to normal tissues have been major drawbacks. One of the strategies for preventing or reducing these side effects is the use of natural radioprotectors such as melatonin. Melatonin is largely secreted in the pineal glands of mammals. Studies have evaluated its radioprotective effect mostly using animal models. However, in this review, we discuss the findings of various clinical studies that utilized melatonin in radiotherapy. Online databases (PubMed, Scopus, Embase, and Google Scholar) and ClinicalTrials.gov were searched to retrieve relevant clinical studies which utilized melatonin alongside radiotherapy. The literature reviewed showed that melatonin administration prevented radiation-induced dermatitis, delayed the onset of oral mucositis, and improved treatment outcomes as well as patients’ quality of life after radiotherapy. These studies reported minimal toxicities from melatonin administration. However, their results were not in agreement in terms of patient survival. The application of melatonin in radiotherapy showed potentials for improving treatment outcomes as well as preventing or ameliorating radiotherapy-induced side effects. We recommend further clinical trials for more insights especially in areas such as optimal melatonin dose and patient survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Ståhl E, Ceberg J, Einhorn N, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001--summary and conclusions. Acta Oncol. 2003;42(5–6):357–65.

    Article  PubMed  Google Scholar 

  2. Thariat J, Hannoun-Levi J-M, Myint AS, Vuong T, Gérard J-P. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol. 2013;10(1):52–60.

    Article  CAS  PubMed  Google Scholar 

  3. Narmani A, Farhood B, Haghi-Aminjan H, Mortezazadeh T, Aliasgharzadeh A, Mohseni M, et al. Gadolinium nanoparticles as diagnostic and therapeutic agents: their delivery systems in magnetic resonance imaging and neutron capture therapy. J Drug Del Sci Technol. 2018;44:457–66.

    Article  CAS  Google Scholar 

  4. Schardt D, Elsässer T, Schulz-Ertner D. Heavy-ion tumor therapy: physical and radiobiological benefits. Rev Mod Phys. 2010;82(1):383–425.

    Article  Google Scholar 

  5. Najafi M, Fardid R, Takhshid MA, Mosleh-Shirazi MA, Rezaeyan A-H, Salajegheh A. Radiation-induced oxidative stress at out-of-field lung tissues after pelvis irradiation in rats. Cell J. 2016;18(3):340–5.

    PubMed  PubMed Central  Google Scholar 

  6. Peña LA, Fuks Z, Koksnick R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem Pharmacol. 1997;53(5):615–21.

    Article  PubMed  Google Scholar 

  7. Pena LA, Fuks Z, Kolesnick RN. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res. 2000;60(2):321–7.

    CAS  PubMed  Google Scholar 

  8. Devi PU, Agrawala PK. Normal tissue protectors against radiation injury. Def Sci J. 2011;61(2):105–12.

    Article  CAS  Google Scholar 

  9. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem. 2009;16(2):130–43.

    Article  CAS  PubMed  Google Scholar 

  10. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9(2):134–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist. 2010;15(4):360–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov Today. 2007;12(19–20):794–805.

    Article  CAS  PubMed  Google Scholar 

  13. Rosen EM, Day R, Singh VK. New approaches to radiation protection. Front Oncol. 2015;4:381.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Farhood B, Goradel N, Mortezaee K, Khanlarkhani N, Salehi E, Nashtaei M, et al. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clin Transl Oncol. 2019;21(3):268–79.

  15. Reiter RJ, Tan D-X, Herman TS, Thomas CR Jr. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys. 2004;59(3):639–53.

    Article  CAS  PubMed  Google Scholar 

  16. Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med. 2009;11(11):e5 https://doi.org/10.1017/S1462399409000982.

  17. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186–95.

    Article  CAS  PubMed  Google Scholar 

  18. Allegra M, Reiter R, Tan DX, Gentile C, Tesoriere L, Livrea M. The chemistry of melatonin’s interaction with reactive species. J Pineal Res. 2003;34(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  19. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature’s most versatile biological signal? FEBS J. 2006;273(13):2813–38.

    Article  CAS  PubMed  Google Scholar 

  20. Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci. 2008;65(13):2001–18.

    Article  CAS  PubMed  Google Scholar 

  21. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin--a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350–84.

    Article  CAS  PubMed  Google Scholar 

  22. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ, et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J. 2004;18(3):537–9.

    Article  CAS  PubMed  Google Scholar 

  23. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27(2):189–200.

    Article  CAS  PubMed  Google Scholar 

  24. Meng X, Li Y, Li S, Zhou Y, Gan RY, Xu DP, et al. Dietary sources and bioactivities of melatonin. Nutrients. 2017;9(4):367.

  25. Snyder SH, Axelrod J, Zweig M. Circadian rhythm in the serotonin content of the rat pineal gland: regulating factors. J Pharmacol Exp Ther. 1967;158(2):206–13.

    CAS  PubMed  Google Scholar 

  26. Pelham RW, Vaughan GM, Sandock KL, Vaughan MK. Twenty-four-hour cycle of a melatonin-like substance in the plasma of human males. J Clin Endocrinol Metab. 1973;37(2):341–4.

    Article  Google Scholar 

  27. Fellenberg AJ, Phillipou G, Seamark RF. Measurement of urinary production rates of melatonin as an index of human pineal function. Endocr Res Commun. 1980;7(3):167–75.

    Article  CAS  PubMed  Google Scholar 

  28. Waldhauser F, Dietzel M. Daily and annual rhythms in human melatonin secretion: role in puberty control. Ann N Y Acad Sci. 1985;453:205–14.

    Article  CAS  PubMed  Google Scholar 

  29. Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol. 1991;79(1–3):C153–8.

    Article  CAS  PubMed  Google Scholar 

  30. Claustrat B, Geoffriau M, Brun J, Chazot G. Melatonin in humans: a biochemical marker of the circadian clock and an endogenous synchronizer. Neurophysiol Clin. 1995;25(6):351–9.

    Article  CAS  PubMed  Google Scholar 

  31. Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM. Human melatonin production decreases with age. J Pineal Res. 1986;3(4):379–88.

    Article  CAS  PubMed  Google Scholar 

  32. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res. 1993;14(4):151–68.

    Article  CAS  PubMed  Google Scholar 

  33. Reiter RJ, Guerrero JM, Garcia JJ, Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann N Y Acad Sci. 1998;854:410–24.

    Article  CAS  PubMed  Google Scholar 

  34. Vakkuri O. Diurnal rhythm of melatonin in human saliva. Acta Physiol Scand. 1985;124(3):409–12.

    Article  CAS  PubMed  Google Scholar 

  35. Nowak R, McMillen IC, Redman J, Short RV. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol. 1987;27(4):445–52.

    Article  CAS  Google Scholar 

  36. Bornman MS, Oosthuizen JM, Barnard HC, Schulenburg GW, Boomker D, Reif S. Melatonin and sperm motility. Andrologia. 1989;21(5):483–5.

    Article  CAS  PubMed  Google Scholar 

  37. Tan D, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ. High physiological levels of melatonin in the bile of mammals. Life Sci. 1999;65(23):2523–9.

    Article  CAS  PubMed  Google Scholar 

  38. Hedlund L, Lischko MM, Rollag MD, Niswender GD. Melatonin: daily cycle in plasma and cerebrospinal fluid of calves. Science. 1977;195(4279):686–7.

    Article  CAS  PubMed  Google Scholar 

  39. Shaw PF, Kennaway DJ, Seamark RF. Evidence of high concentrations of melatonin in lateral ventricular cerebrospinal fluid of sheep. J Pineal Res. 1989;6(3):201–8.

    Article  CAS  PubMed  Google Scholar 

  40. Rousseau A, Petren S, Plannthin J, Eklundh T, Nordin C. Serum and cerebrospinal fluid concentrations of melatonin: a pilot study in healthy male volunteers. J Neural Transm (Vienna). 1999;106(9–10):883–8.

    Article  CAS  Google Scholar 

  41. Young IM, Leone RM, Francis P, Stovell P, Silman RE. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab. 1985;60(1):114–9.

    Article  CAS  PubMed  Google Scholar 

  42. Raynaud F, Mauviard F, Geoffriau M, Claustrat B, Pevet P. Plasma 6-hydroxymelatonin, 6-sulfatoxymelatonin and melatonin kinetics after melatonin administration to rats. Biol Signals. 1993;2(6):358–66.

    Article  CAS  PubMed  Google Scholar 

  43. Tan DX, Manchester LC, Reiter RJ, Plummer BF. Cyclic 3-hydroxymelatonin: a melatonin metabolite generated as a result of hydroxyl radical scavenging. Biol Signals Recept. 1999;8(1–2):70–4.

    Article  CAS  PubMed  Google Scholar 

  44. Galano A, Tan DX, Reiter RJ. Melatonin: A Versatile Protector against Oxidative DNA Damage. Molecules. 2018;23(3):530.

  45. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys. 2001;34(2):237–56.

    Article  CAS  PubMed  Google Scholar 

  46. Karbownik M, Reiter RJ. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. Proc Soc Exp Biol Med. 2000;225(1):9–22.

    Article  CAS  PubMed  Google Scholar 

  47. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002;2(2):181–97.

    Article  CAS  PubMed  Google Scholar 

  48. Abbaszadeh A, Haddadi GH, Haddadi Z. Melatonin role in ameliorating radiation-induced skin damage: from theory to practice (a review of literature). J Biomed Phys Eng. 2017;7(2):127–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Sener G, Atasoy BM, Ersoy Y, Arbak S, Sengoz M, Yegen BC. Melatonin protects against ionizing radiation-induced oxidative damage in corpus cavernosum and urinary bladder in rats. J Pineal Res. 2004;37(4):241–6.

    Article  CAS  PubMed  Google Scholar 

  50. Sener G, Jahovic N, Tosun O, Atasoy BM, Yegen BC. Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. Life Sci. 2003;74(5):563–72.

    Article  CAS  PubMed  Google Scholar 

  51. Shabeeb D, Najafi M, Musa AE, Keshavarz M, Shirazi A, Hassanzadeh G, et al. Biochemical and histopathological evaluation of the radioprotective effects of melatonin against gamma ray-induced skin damage. Curr Radiopharm. 2019;12(1):72–81.

    Article  CAS  PubMed  Google Scholar 

  52. Taysi S, Koc M, Buyukokuroglu ME, Altinkaynak K, Sahin YN. Melatonin reduces lipid peroxidation and nitric oxide during irradiation-induced oxidative injury in the rat liver. J Pineal Res. 2003;34(3):173–7.

    Article  CAS  PubMed  Google Scholar 

  53. El-Missiry MA, Fayed TA, El-Sawy MR, El-Sayed AA. Ameliorative effect of melatonin against gamma-irradiation-induced oxidative stress and tissue injury. Ecotoxicol Environ Saf. 2007;66(2):278–86.

    Article  CAS  PubMed  Google Scholar 

  54. Shirazi A, Mihandoost E, Ghobadi G, Mohseni M, Ghazi-Khansari M. Evaluation of radio-protective effect of melatonin on whole body irradiation induced liver tissue damage. Cell J. 2013;14(4):292–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Karslioglu I, Ertekin MV, Taysi S, Kocer I, Sezen O, Gepdiremen A, et al. Radioprotective effects of melatonin on radiation-induced cataract. J Radiat Res. 2005;46(2):277–82.

    Article  CAS  PubMed  Google Scholar 

  56. Shirazi A, Haddadi GH, Asadi-Amoli F, Sakhaee S, Ghazi-Khansari M, Avand A. Radioprotective effect of melatonin in reducing oxidative stress in rat lenses. Cell J. 2011;13(2):79–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Sharma S, Haldar C. Melatonin prevents X-ray irradiation induced oxidative damagein peripheral blood and spleen of the seasonally breeding rodent, Funambulus pennanti during reproductively active phase. Int J Radiat Biol. 2006;82(6):411–9.

    Article  CAS  PubMed  Google Scholar 

  58. Sharma S, Haldar C, Chaube SK, Laxmi T, Singh SS. Long-term melatonin administration attenuates low-LET gamma-radiation-induced lymphatic tissue injury during the reproductively active and inactive phases of Indian palm squirrels (Funambulus pennanti). Br J Radiol. 2010;83(986):137–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Sharma S, Haldar C, Chaube SK. Effect of exogenous melatonin on X-ray induced cellular toxicity in lymphatic tissue of Indian tropical male squirrel, Funambulus pennanti. Int J Radiat Biol. 2008;84(5):363–74.

    Article  CAS  PubMed  Google Scholar 

  60. Erol FS, Topsakal C, Ozveren MF, Kaplan M, Ilhan N, Ozercan IH, et al. Protective effects of melatonin and vitamin E in brain damage due to gamma radiation: an experimental study. Neurosurg Rev. 2004;27(1):65–9.

    Article  PubMed  Google Scholar 

  61. Aghazadeh S, Azarnia M, Shirazi A, Mahdavi SR, Zangii BM. Melatonin as a protective agent in spinal cord damage after gamma irradiation. Rep Pract Oncol Radiother. 2007;12(2):95–9.

    Article  Google Scholar 

  62. Haddadi G, Shirazi A, Sepehrizadeh Z, Mahdavi SR, Haddadi M. Radioprotective effect of melatonin on the cervical spinal cord in irradiated rats. Cell J. 2013;14(4):246–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 1995;33(4):781–96.

    Article  CAS  PubMed  Google Scholar 

  65. Shirazi A, Haddadi G, Minaee B, Sepehrizadeh Z, Mahdavi S, Jaberi E, et al. Evaluation of melatonin for modulation of apoptosis-related genes in irradiated cervical spinal cord. Int J Low Radiat. 2010;7(6):436–45.

    Article  CAS  Google Scholar 

  66. Mohseni M, Mihandoost E, Shirazi A, Sepehrizadeh Z, Bazzaz JT, Ghazi-khansari M. Melatonin may play a role in modulation of bax and bcl-2 expression levels to protect rat peripheral blood lymphocytes from gamma irradiation-induced apoptosis. Mutat Res. 2012;738–739:19–27.

    Article  CAS  PubMed  Google Scholar 

  67. Jang SS, Kim WD, Park WY. Melatonin exerts differential actions on X-ray radiation-induced apoptosis in normal mice splenocytes and Jurkat leukemia cells. J Pineal Res. 2009;47(2):147–55.

    Article  CAS  PubMed  Google Scholar 

  68. Alonso-Gonzalez C, Menendez-Menendez J, Gonzalez-Gonzalez A, Gonzalez A, Cos S, Martinez-Campa C. Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF7 human breast cancer cells. Int J Oncol. 2018;52(2):560–70.

    CAS  PubMed  Google Scholar 

  69. Maestroni GJ. T-helper-2 lymphocytes as a peripheral target of melatonin. J Pineal Res. 1995;18(2):84–9.

    Article  CAS  PubMed  Google Scholar 

  70. Wu CC, Lu KC, Lin GJ, Hsieh HY, Chu P, Lin SH, et al. Melatonin enhances endogenous heme oxygenase-1 and represses immune responses to ameliorate experimental murine membranous nephropathy. J Pineal Res. 2012;52(4):460–9.

    Article  CAS  PubMed  Google Scholar 

  71. Bondy SC, Lahiri DK, Perreau VM, Sharman KZ, Campbell A, Zhou J, et al. Retardation of brain aging by chronic treatment with melatonin. Ann N Y Acad Sci. 2004;1035:197–215.

    Article  CAS  PubMed  Google Scholar 

  72. Fernandez-Gil B, Moneim AE, Ortiz F, Shen YQ, Soto-Mercado V, Mendivil-Perez M, et al. Melatonin protects rats from radiotherapy-induced small intestine toxicity. PLoS One. 2017;12(4):e0174474.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Najafi M, Shirazi A, Motevaseli E, Geraily G, Norouzi F, Heidari M, et al. The melatonin immunomodulatory actions in radiotherapy. Biophys Rev. 2017;9(2):139–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Leon J, Casado J, Jimenez Ruiz SM, Zurita MS, Gonzalez-Puga C, Rejon JD, et al. Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-kappabeta. J Pineal Res. 2014;56(4):415–26.

    Article  CAS  PubMed  Google Scholar 

  75. Cos S, Blask DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res. 1994;17(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  76. Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998;58(19):4383–90.

    CAS  PubMed  Google Scholar 

  77. Jardim-Perassi BV, Lourenco MR, Doho GM, Grigolo IH, Gelaleti GB, Ferreira LC, et al. Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. Anti Cancer Agents Med Chem. 2016;16(3):347–58.

    Article  CAS  Google Scholar 

  78. Raben D, Helfrich B. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer? Clin Lung Cancer. 2004;6(1):48–57.

    Article  CAS  PubMed  Google Scholar 

  79. Alonso-Gonzalez C, Gonzalez A, Martinez-Campa C, Menendez-Menendez J, Gomez-Arozamena J, Garcia-Vidal A, et al. Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis. Cancer Lett. 2016;370(1):145–52.

    Article  CAS  PubMed  Google Scholar 

  80. Stevens RG. Working against our endogenous circadian clock: breast cancer and electric lighting in the modern world. Mutat Res. 2009;680(1–2):106–8.

    Article  CAS  PubMed  Google Scholar 

  81. Zhao M, Wan J, Zeng K, Tong M, Lee AC, Ding J, et al. The reduction in circulating melatonin level may contribute to the pathogenesis of ovarian cancer: a retrospective study. J Cancer. 2016;7(7):831–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Li Y, Li S, Zhou Y, Meng X, Zhang J-J, Xu D-P, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24):39896–921.

    PubMed  PubMed Central  Google Scholar 

  83. Wang YM, Jin BZ, Ai F, Duan CH, Lu YZ, Dong TF, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012;69(5):1213–20.

    Article  CAS  PubMed  Google Scholar 

  84. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999;65(4):415–20.

    Article  CAS  PubMed  Google Scholar 

  85. Girgert R, Bartsch C, Hill SM, Kreienberg R, Hanf V. Tracking the elusive antiestrogenic effect of melatonin: a new methodological approach. Neuro Endocrinol Lett. 2003;24(6):440–4.

    CAS  PubMed  Google Scholar 

  86. Martinez-Campa C, Alonso-Gonzalez C, Mediavilla MD, Cos S, Gonzalez A, Ramos S, et al. Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J Pineal Res. 2006;40(4):291–6.

    Article  CAS  PubMed  Google Scholar 

  87. Cos S, Martinez-Campa C, Mediavilla MD, Sanchez-Barcelo EJ. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. 2005;38(2):136–42.

    Article  CAS  PubMed  Google Scholar 

  88. Collins A, Yuan L, Kiefer TL, Cheng Q, Lai L, Hill SM. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett. 2003;189(1):49–57.

    Article  CAS  PubMed  Google Scholar 

  89. Cos S, Mediavilla MD, Fernandez R, Gonzalez-Lamuno D, Sanchez-Barcelo EJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res. 2002;32(2):90–6.

    Article  CAS  PubMed  Google Scholar 

  90. Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat. 2009;118(2):293–305.

    Article  CAS  PubMed  Google Scholar 

  91. Alonso-Gonzalez C, Gonzalez A, Martinez-Campa C, Gomez-Arozamena J, Cos S. Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. J Pineal Res. 2015;58(2):189–97.

    Article  CAS  PubMed  Google Scholar 

  92. Lozano A, Marruecos J, Rubió-Casadevall J, Farre N, Lopez-Pousa A, Giralt J, et al. Phase II trial of high-dose melatonin oral gel for the prevention and treatment of oral mucositis in H&N cancer patients undergoing chemoradiation (MUCOMEL). J Clin Oncol. 2018;36(15_suppl):6007.

    Article  Google Scholar 

  93. Fernández-Tresguerres A. Radiodermitis prevention. An R Acad Nac Med (Madr). 2018;135(01):13–9.

    Google Scholar 

  94. Onseng K, Johns NP, Khuayjarernpanishk T, Subongkot S, Priprem A, Hurst C, et al. Beneficial effects of adjuvant melatonin in minimizing oral mucositis complications in head and neck cancer patients receiving concurrent chemoradiation. J Altern Complement Med. 2017;23(12):957–63.

    Article  PubMed  Google Scholar 

  95. Ben-David MA, Elkayam R, Gelernter I, Pfeffer RM. Melatonin for prevention of breast radiation dermatitis: a phase II, prospective, double-blind randomized trial. Isr Med Assoc J. 2016;18(3–4):188–92.

    PubMed  Google Scholar 

  96. Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. In Vivo. 2008;22(3):397–400.

    CAS  PubMed  Google Scholar 

  97. Berk L, Berkey B, Rich T, Hrushesky W, Blask D, Gallagher M, et al. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys. 2007;68(3):852–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996;53(1):43–6.

    Article  CAS  PubMed  Google Scholar 

  99. Raben M, Walach N, Galili U, Schlesinger M. The effect of radiation therapy on lymphocyte subpopulations in cancer patients. Cancer. 1976;37(3):1417–21.

    Article  CAS  PubMed  Google Scholar 

  100. MacLennan IC, Kay HE. Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation. Cancer. 1978;41(1):108–11.

    Article  CAS  PubMed  Google Scholar 

  101. Idestrom K, Petrini B, Blomgren H, Wasserman J, Wallgren A, Baral E. Changes of the peripheral lymphocyte population following radiation therapy to extended and limited fields. Int J Radiat Oncol Biol Phys. 1979;5(10):1761–6.

    Article  CAS  PubMed  Google Scholar 

  102. Lissoni P, Meregalli S, Bonetto E, Mancuso M, Brivio F, Colciago M, et al. Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms. J Biol Regul Homeost Agents. 2005;19(3–4):153–8.

    CAS  PubMed  Google Scholar 

  103. Vijayalaxmi TCR Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002;20(10):2575–601.

    Article  CAS  PubMed  Google Scholar 

  104. Prise KM, Saran A. Concise review: stem cell effects in radiation risk. Stem Cells. 2011;29(9):1315–21.

    CAS  PubMed  Google Scholar 

  105. Fischer TW, Elsner P. The antioxidative potential of melatonin in the skin. Curr Probl Dermatol. 2001;29:165–74.

    Article  CAS  PubMed  Google Scholar 

  106. Fischer TW, Greif C, Fluhr JW, Wigger-Alberti W, Elsner P. Percutaneous penetration of topically applied melatonin in a cream and an alcoholic solution. Skin Pharmacol Physiol. 2004;17(4):190–4.

    Article  CAS  PubMed  Google Scholar 

  107. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253–62.

    Article  PubMed  Google Scholar 

  108. Itoh Y, Kubota S, Kawamura M, Nomoto Y, Murao T, Yamakawa K, et al. A multicenter survey of stage T1 glottic cancer treated with radiotherapy delivered in 2.25-Gy fractions in clinical practice: an initial 5-year analysis. Nagoya J Med Sci. 2016;78(4):399–406.

    PubMed  PubMed Central  Google Scholar 

  109. Epstein JB, Schubert MM. Managing pain in mucositis. Semin Oncol Nurs. 2004;20(1):30–7.

    Article  PubMed  Google Scholar 

  110. Harris DJ. Cancer treatment-induced mucositis pain: strategies for assessment and management. Ther Clin Risk Manag. 2006;2(3):251–8.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer treatment: natural history, prevention and treatment. Mol Clin Oncol. 2014;2(3):337–40.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Kyriakopoulos CE, Braden AM, Kolesar JM, Eickhoff JC, Bailey HH, Heideman J, et al. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Investig New Drugs. 2017;35(3):290–7.

    Article  CAS  Google Scholar 

  113. Sonis ST. Oral mucositis in head and neck cancer: risk, biology, and management. Am Soc Clin Oncol Educ Book. 2013;33:e236–40.

    Article  Google Scholar 

  114. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab. 2009;5(2):88–99.

    Article  CAS  PubMed  Google Scholar 

  115. Darzy KH. Radiation-induced hypopituitarism. Curr Opin Endocrinol Diabetes Obes. 2013;20(4):342–53.

    Article  CAS  PubMed  Google Scholar 

  116. Darzy KH, Shalet SM. Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. Growth Hormon IGF Res. 2006;16(Suppl A):S30–40.

    Article  CAS  Google Scholar 

  117. Reim ASD, Saletu-Zyhlarz G, Preusser M, Schmook MT, Dieckmann K, Zielinski CC, et al. Successful treatment of insomnia with melatonin in a patient with malignant glioma after radiotherapy-involving the pineal gland. Clin Med Rev Case Rep. 2016;3(6):112–4.

    Article  Google Scholar 

  118. Di WL, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med. 1997;336(14):1028–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Physics, Tehran University of Medical Sciences (TUMS), International Campus, Tehran, Iran

    Ahmed Eleojo Musa

  2. Research Center for Molecular and Cellular Imaging, TUMS, Tehran, Iran

    Ahmed Eleojo Musa

  3. Department of Physiology, College of Medicine, University of Misan, Amarah, Iraq

    Dheyauldeen Shabeeb

  4. Misan Radiotherapy Center, Misan Health Directorate, Ministry of Health/Environment,Misan, Amarah, Misan, Iraq

    Dheyauldeen Shabeeb

  5. Department of Physics, University of Guilan, Rasht, Guilan, Iran

    Gilnaz Omyan

  6. Radiotherapy and Oncology Research Center, Cancer Institute, TUMS, Tehran, Iran

    Gilnaz Omyan

Authors
  1. Ahmed Eleojo Musa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dheyauldeen Shabeeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gilnaz Omyan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed Eleojo Musa.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Musa, A.E., Shabeeb, D. & Omyan, G. Clinical Applications of Melatonin in Radiotherapy: a Review. SN Compr. Clin. Med. 1, 575–583 (2019). https://doi.org/10.1007/s42399-019-00100-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42399-019-00100-6

Keywords

Search

Navigation